文献速递创伤与烧伤重症综合管理与镇静镇痛

创伤患者静脉血栓栓塞预防:普通肝素与低分子肝素比较

Unfractionated heparin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in trauma.
PubMed 文献 · J Trauma Acute Care Surg · 2017-01-01
一句话结论在住院创伤患者中,低分子肝素较普通肝素降低死亡率(OR 0.64)和静脉血栓栓塞事件(OR 0.67),作者认为低分子肝素应作为首选预防药物。

该研究利用密歇根创伤质量改进项目2012年1月至2014年12月的数据,纳入23家医院、损伤严重度评分≥5且住院超过24小时的创伤患者,比较首次预防剂量使用低分子肝素与普通肝素对结局的影响。分析队列共18,010例,经风险调整并考虑医院效应后,低分子肝素组死亡率(OR 0.64,95%CI 0.49-0.83)、静脉血栓栓塞事件(OR 0.67,95%CI 0.53-0.84)、肺栓塞(OR 0.53,95%CI 0.35-0.79)和深静脉血栓(OR 0.73,95%CI 0.57-0.95)风险均低于普通肝素组。低分子肝素降低静脉血栓栓塞风险在较低损伤严重度类别患者中最为明显。作者结论认为低分子肝素优于普通肝素,应作为住院创伤患者首选的静脉血栓栓塞预防药物。

要点

  • 在住院创伤患者中,低分子肝素组死亡率低于普通肝素组(OR 0.64,95%CI 0.49-0.83)。
  • 低分子肝素组静脉血栓栓塞事件风险低于普通肝素组(OR 0.67,95%CI 0.53-0.84)。
  • 低分子肝素组肺栓塞风险低于普通肝素组(OR 0.53,95%CI 0.35-0.79),深静脉血栓风险亦较低(OR 0.73,95%CI 0.57-0.95)。
  • 低分子肝素降低静脉血栓栓塞风险在较低损伤严重度类别患者中最为明显。
  • 东部创伤外科协会指南推荐低分子肝素作为创伤患者首选的静脉血栓栓塞预防药物。

适用人群与场景

  • 密歇根创伤质量改进项目2012年1月至2014年12月数据中,来自23家医院、损伤严重度评分≥5且住院超过24小时的创伤患者。
  • 排除标准:24小时内死亡、未接受药物性静脉血栓栓塞预防、或住院期间使用普通肝素和低分子肝素以外药物进行预防的患者。

研究设计与关键结果

  • 研究类型:基于密歇根创伤质量改进项目数据的比较效果研究,纳入23家医院、37,868例筛出患者,最终分析队列18,010例。
  • 干预与对照:比较首次预防剂量使用低分子肝素与普通肝素(普通肝素为参照)对住院期间结局的影响,模型纳入首次预防给药时机及标准协变量。
  • 主要终点:低分子肝素组死亡率低于普通肝素组(OR 0.64,95%CI 0.49-0.83)。
  • 关键次要终点:低分子肝素组静脉血栓栓塞事件(OR 0.67,95%CI 0.53-0.84)、肺栓塞(OR 0.53,95%CI 0.35-0.79)、深静脉血栓(OR 0.73,95%CI 0.57-0.95)风险均低于普通肝素组。
  • 亚组结果:低分子肝素降低静脉血栓栓塞风险在较低损伤严重度类别患者中最为明显。

证据类型、等级与局限

  • 证据类型:基于质量改进项目数据的比较效果研究;证据等级:治疗性,III级。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为低分子肝素在降低创伤患者死亡率和静脉血栓栓塞事件方面优于普通肝素,低分子肝素应作为住院创伤患者首选的静脉血栓栓塞预防药物。
  • 东部创伤外科协会指南推荐低分子肝素作为创伤患者首选的静脉血栓栓塞预防药物。

指南或共识出处

  • 东部创伤外科协会指南推荐低分子肝素作为创伤患者首选的静脉血栓栓塞预防药物(原文引用)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Venous thromboembolism (VTE) is a common complication in trauma patients. Pharmacologic prophylaxis is utilized in trauma patients to reduce their risk of a VTE event. The Eastern Association for the Surgery of Trauma guidelines recommend use of low-molecular-weight heparin (LMWH) as the preferred agent in these patients. However, there is literature suggesting that unfractionated heparin (UFH) is an acceptable, and less costly, alternative VTE prophylaxis agent with equivalent efficacy in trauma patients. We examined data from the Michigan Trauma Quality Improvement Program to perform a comparative effectiveness study of UFH versus LMWH on outcomes for trauma patients.

METHODS: We conducted an analysis of the Michigan Trauma Quality Improvement Program data from January 2012 to December 2014. The data set contains information on date, time, and drug type of the first dose of VTE prophylaxis. Thirty-seven thousand eight hundred sixty-eight patients from 23 hospitals were present with an Injury Severity Score of 5 or greater and hospitalization for more than 24 hours. Patients were excluded if they died within 24 hours or received no pharmacologic VTE prophylaxis or agents other than UFH or LMWH while admitted to the hospital. We compared patients receiving LMWH to those receiving UFH. Outcomes assessed were VTE event, pulmonary embolism, deep vein thrombosis, and mortality during hospitalization. We used a generalized estimating equation approach to fit population-averaged logistic regression models with the type of first dose of VTE prophylaxis as the independent variable. Unfractionated heparin was considered the reference value. Timing of the first dose of VTE prophylaxis was entered into the model in addition to standard covariates. Odds ratios were generated for each of the dependent variables of interest.

RESULTS: The analysis cohort consisted of 18,010 patients. Patients administered LMWH had a decreased risk of mortality (odds ratio, 0.64; confidence interval, 0.49-0.83), VTE (odds ratio, 0.67; confidence interval, 0.53-0.84), pulmonary embolism (odds ratio, 0.53; confidence interval, 0.35-0.79), and deep vein thrombosis (odds ratio, 0.73; confidence interval, 0.57-0.95) when compared with UFH following risk adjustment and accounting for hospital effect. The reduced risk of a VTE event for patients receiving LMWH was most pronounced for patients in the lower injury-severity categories.

CONCLUSIONS: In our examination of VTE prophylaxis drug effectiveness, LMWH was found to be superior to UFH in reducing the incidence of mortality and VTE events among trauma patients. Therefore, LMWH should be the preferred VTE prophylaxis agent for use in hospitalized trauma patients.

LEVEL OF EVIDENCE: Therapeutic, level III.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Jacobs BN, Cain-Nielsen AH, Jakubus JL, et al. Unfractionated heparin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in trauma. J Trauma Acute Care Surg. 2017. PMID: 28426561. doi:10.1097/TA.0000000000001494

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。